Syneron Medical, Ltd., has announced the release of evolastin, an energy-based dermal remodeling procedure that is, according to the company, the industry’s first energy-based process for facial remodeling.
The latest device from Syneron delivers controlled radiofrequency energy directly into the deep dermis to stimulate the skin’s natural production of collagen, elastin and hyaluronic acid in one treatment. All the energy generated by evolastin is aimed directly at the base of the dermis; this is a novel approach compared to other similar procedures, where the dermis is reached through the surface, according to Syneron. A randomized, blinded clinical study published in Archives of Dermatology showed “continual textual, tone or elasticity in addition to volumetric improvements for up to eighteen months post-procedure.” Patient satisfaction was also “remarkably high and equally consistent.”
The evolastin procedure can generally be performed with local anesthetic in about an hour, according to Syneron. Patients can typically return to normal activities within 24 hours of evolastin and downtime is minimal, with minor redness, swelling or bruising for a few days.
In a statement, Louis P. Scafuri, CEO of Syneron Medical, said: “evolastin represents our commitment to scientific research and technological development. The unique results of evolastin, coupled with strong clinical evidence, provides a unique, minimally invasive solution for our customers, a revolutionary alternative for their patients and yet another exciting advancement in our field.”
